TYK MEDICINES-B (02410) Surges Over 10% as TY-9591 Tablets Designated for Priority Review

Like
Comment
Favorite

TYK MEDICINES-B (02410) Surges Over 10% as TY-9591 Tablets Designated for Priority Review

Stock News01-07

TYK MEDICINES-B (02410) rose more than 10%, and as of the time of writing, it was up 7.97% to HKD 13.95, with a turnover of HKD 32.6634 million. On January 6, the CDE website indicated that the Mesylate Edotinib Tablets (TY-9591 tablets) declared by TYK MEDICINES are planned to be included in the priority review process. The drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, and are accompanied by central nervous system (CNS) metastases. It is worth mentioning that at the World Lung Cancer Congress last September, the key Phase II clinical trial results for Edotinib tablets targeting NSCLC brain metastases, released by TYK MEDICINES, garnered significant attention from industry peers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1135622162?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135622162","market":"nz","top_or_hot":-1,"title":"TYK MEDICINES-B (02410) Surges Over 10% as TY-9591 Tablets Designated for Priority Review","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) rose more than 10%, and as of the time of writing, it was up 7.97% to HKD 13.95, with a turnover of HKD 32.6634 million.\nOn January 6, the CDE website indicated that the Mesylate Edotinib Tablets (TY-9591 tablets) declared by TYK MEDICINES are planned to be included in the priority review process.\nThe drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, and are accompanied by central nervous system (CNS) metastases.\nIt is worth mentioning that at the World Lung Cancer Congress last September, the key Phase II clinical trial results for Edotinib tablets targeting NSCLC brain metastases, released by TYK MEDICINES, garnered significant attention from industry peers.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK MEDICINES-B (02410) Surges Over 10% as TY-9591 Tablets Designated for Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK MEDICINES-B (02410) Surges Over 10% as TY-9591 Tablets Designated for Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-07 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) rose more than 10%, and as of the time of writing, it was up 7.97% to HKD 13.95, with a turnover of HKD 32.6634 million.\nOn January 6, the CDE website indicated that the Mesylate Edotinib Tablets (TY-9591 tablets) declared by TYK MEDICINES are planned to be included in the priority review process.\nThe drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, and are accompanied by central nervous system (CNS) metastases.\nIt is worth mentioning that at the World Lung Cancer Congress last September, the key Phase II clinical trial results for Edotinib tablets targeting NSCLC brain metastases, released by TYK MEDICINES, garnered significant attention from industry peers.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1135622162","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135622162","pubTimestamp":1767750500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) rose more than 10%, and as of the time of writing, it was up 7.97% to HKD 13.95, with a turnover of HKD 32.6634 million. On January 6, the CDE website indicated that the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1161":"生物科技","BK1574":"生物医药B类股","02410":"同源康医药-B","09939":"开拓药业-B","TY":"Tri-Continental Corp","BK1515":"抗疫概念"},"translate_title":"泰克医药-B(02410)因TY-9591片剂被指定优先审评而飙升逾10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02410":1,"09939":1,"TY":1},"content_text":"TYK MEDICINES-B (02410) rose more than 10%, and as of the time of writing, it was up 7.97% to HKD 13.95, with a turnover of HKD 32.6634 million.\nOn January 6, the CDE website indicated that the Mesylate Edotinib Tablets (TY-9591 tablets) declared by TYK MEDICINES are planned to be included in the priority review process.\nThe drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, and are accompanied by central nervous system (CNS) metastases.\nIt is worth mentioning that at the World Lung Cancer Congress last September, the key Phase II clinical trial results for Edotinib tablets targeting NSCLC brain metastases, released by TYK MEDICINES, garnered significant attention from industry peers.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}